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Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) is
probably the most important ubiquitously expressed
little protein that you have never heard of. Discovered
more than 20 years ago, it is now known as a master
regulator of redox homeostasis, controlling a plethora of
cytoprotective phase II anti-oxidant enzymes. Regulation
of gene expression by histone acetyltransferases and
histone deacetylases drives the etiology of many
age-related human diseases, including osteoarthritis. In
Arthritis Research & Therapy, Cai et al. explore systemic
histone deacetylase inhibition as a strategy to prevent
osteoarthritis and identify a role for Nrf2 in preventing
cartilage degeneration.ing histones and chromatin structure is too simple.In Arthritis Research & Therapy, Cai et al. used a broad-
spectrum histone deacetylase (HDAC) inhibitor (HDACi)
and compared histological cartilage degradation between
wild-type and Nrf2 (nuclear factor (erythroid-derived 2)-
like 2) knockout mice, as well as expression of matrix
metalloproteinases (MMPs), to conclude that acetylation-
activated Nrf2 mediates HDACi protection against osteo-
arthritis (OA) [1].
Although certain OA susceptibility loci predict the risk
for disease development, environmental parameters de-
termine the individual disease progression. Epigenetic
modifications are a mitotically heritable means by which
cells can regulate gene expression, often in response to
environmental changes. Actual gene expression in a cell
relies on a complex interplay between the general acces-
sibility of a coding region on the basis of the structural
packaging status of the chromatin and the activation of
the gene promoter by transcription (co-)factors. BasicCorrespondence: hjahr@ukaachen.de
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RNAs, DNA methylation, and histone variants and their
modifications [2]. These post-translational histone modifi-
cations, comprising acetylation, phosphorylation, methyla-
tion, and ubiquitination [3], can act in a concerted fashion
to regulate the genome accessibility, also referred to as the
histone code. Acetylation occurs on specific lysine resi-
dues on the N-terminal tails of histones, mediated by
histone acetyltransferases (HATs), which loosen the
histone–DNA interaction, allowing access to the tran-
scriptional apparatus in the euchromatin. In contrast,
HDACs (EC 3.5.1.98) remove these acetyl groups to con-
dense DNA into heterochromatin. Although that appears
to be their predominant function, regarding HDACs solely
in the context of regulating gene transcription by modify-
HDACs are interacting with a variety of non-histone
proteins; some of these are transcription factors and co-
regulators, some are not. Although our knowledge about
the role of DNA methylation in OA is increasing [4], ef-
fects of the histone code remain largely enigmatic. None-
theless, age-related loss of normal epigenetic patterns is
associated with numerous human diseases.
Nrf2 is a “thermostat” within our cells that senses the
level of cellular stress and turns on internal protective
mechanisms to orchestrate cellular defense; Nrf2 is con-
trolled by its adaptor protein Keap1 (Kelch-like ECH-
associated protein 1), which regulates its proteasomal
degradation. Because Nrf2 is involved in several degen-
erative diseases in multiple organs [5], biogerontologists
proposed that exposing cells to mild stress should result
in a beneficial adaptive hermetic response. In fact, Nrf2
activation developed an imago as potential cure for all
age-related diseases. Very potent Nrf2 activators were
found in many cruciferous vegetables like cabbage, dis-
playing anti-inflammatory and anti-oxidant activities [6].
Whereas the Medical School of Warwick University
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evaluating traditional cabbage leaf cataplasms for treat-
ing primary symptomatic knee OA. However, a currently
emerging “dark side” indicates that Nrf2 may in a
context-dependent manner even promote diseases [5],
which may result from divergent responses to intrinsic
and extrinsic cellular stress. So, eat your veggies, but
keep in mind that superfood is unlikely to become our
first-line treatment for OA.
Cai et al. used trichostatin A (TSA) as an HDACi and
this choice has important limitations because TSA has
poor pharmacokinetics and does not discriminate between
HDAC isozymes [7]. Recent data further demonstrate a
crosstalk between nuclear factor-kappa-B (NF-κB) and
Nrf2 in the inflammatory pathway. The p65 subunit of
NF-κB is itself controlled by acetylation and deacetylation
(via HDAC3 and HDAC6), and NF-κB modulates expres-
sion of MMP-1, MMP-3, and MMP-13 in cytokine-
stimulated cells. MMP-1 and MMP-13, being able to
degrade native cartilage-specific type II collagen, are crit-
ical factors of OA progression, but MMPs are also zinc-
dependent endopeptidases and may be directly inhibited
by the zinc-chelator TSA. TSA can further induce partial
relaxation of genomic imprinting and decrease DNA
methylation, while demethylation of the MMP-13 pro-
moter in chondrocytes regulates its expression [8]. Next
to MMPs, HDACs also transcriptionally regulate other
important matrix-degrading enzymes, like key aggreca-
nases [9], contributing to the therapeutic potential of
HDAC inhibition for arthritic diseases.
So, does acetylation-mediated Nrf2 activation exert
this OA-protective effect? The evidence presented by
Cai et al. does point in that direction. Also, monosodium
iodoacetate-induced OA involves reactive oxygen species
in chondrocytes and HDAC inhibition suppresses syn-
ovial inflammation. Heme oxygenase-1, an accepted
Nrf2 target gene, was further shown to mediate benefi-
cial effects on osteoblasts and chondrocytes from pa-
tients with OA. Acetylation of Nrf2 can enhance its
promoter-specific DNA binding and appears to function
in concert with, and downstream of, Keap1-mediated
Nrf2 ubiquitination in modulating its activity [10]. As a
dynamic and reversible process, acetylation of Nrf2 is
determined by the relative activities of HATs and
HDACs, both of whose activities are tightly, but di-
versely, regulated by many signaling pathways.
Is targeting Nrf2 activity by HDAC inhibition a prom-
ising strategy to fight OA? Where Cai et al. started,
others will follow. Because some HDACs, like the sir-
tuins, are not affected by TSA, the good news is that the
number of newly developed HDACis is rapidly increas-
ing [6] to allow more targeted approaches. Anyway, Nrf2
was possibly the most important little protein that you
have never heard of—but that has now changed!Abbreviations
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